Comparison · NCT02002650-6579db76
Pre-ERCP Group vs Post-ERCP Group: Moderate-to-severe Pancreatitis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pre-ERCP Group vs Post-ERCP Group: Moderate-to-severe Pancreatitis. Trial comparisons, record NCT02002650-6579db76. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02002650-6579db76
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00848 | 0.00474 | 0.0151 | wilson | |
| Risk in group 2 | 0.0177 | 0.0118 | 0.0263 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00917 | -0.0186 | -0.000312 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.48 | 0.235 | 0.982 | log | |
| Odds ratio, group 1 over group 2 | 0.476 | 0.231 | 0.981 | log | |
| Number needed to treat, for one fewer participant with the outcome on Pre-ERCP Group than on Post-ERCP Group | 109 | 53.7 | 3,200 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pre-ERCP Group | Pre-ERCP rectal Indomethacin in all patients.~Pre-ERCP rectal Indomethacin: Rectal Indomethacin was administrated within 30min before ERCP in all patients. | 11 | 1,297 | OG000 |
| Group 2 | Post-ERCP Group | Post-ERCP rectal Indomethacin for high-risk patients.~Post-ERCP Rectal Indomethacin: Rectal Indomethacin was administrated immediately after ERCP just for high-risk patients. | 23 | 1,303 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Moderate-to-severe Pancreatitis
- Description
Moderate pancreatitis requiring hospitalization of 4-10 days. Severe pancreatitis requiring hospitalization for more than 10 days, or hemorrhagic pancreatitis, phlegmon or pseudocyst, or intervention (percutaneous drainage or surgery).
- Time frame
- 30 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
- NCT number
- NCT02002650
- Phases
- NA
- Conditions
- Post-ERCP Acute Pancreatitis
- Interventions
- Pre-ERCP rectal Indomethacin, Post-operational Rectal Indomethacin
- Lead sponsor
- Air Force Military Medical University, China
- Results first posted
- 2016-05-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02002650?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02002650-6579db76